Published in Curr Gastroenterol Rep on December 01, 2012
Pharmacological reports about gastroprotective effects of methanolic extract from leaves of Solidago chilensis (Brazilian arnica) and its components quercitrin and afzelin in rodents. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.79
Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. J Bone Miner Metab (2015) 0.77
A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures. Bonekey Rep (2014) 0.76
Effects of long-term administration of omeprazole on bone mineral density and the mechanical properties of the bone. Rev Bras Ortop (2015) 0.75
Osteopetrorickets due to Snx10 deficiency in mice results from both failed osteoclast activity and loss of gastric acid-dependent calcium absorption. PLoS Genet (2015) 0.75
Analysis of fracture healing in osteopenic bone caused by disuse: experimental study. Braz J Med Biol Res (2016) 0.75
Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53
Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol (2004) 6.90
Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology (1993) 3.98
Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol (2005) 3.86
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest (1999) 3.60
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med (2010) 3.53
Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ (2008) 3.31
Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc (2002) 3.09
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med (2005) 2.98
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet (1997) 2.78
Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ (2012) 2.45
Calcium absorption and achlorhydria. N Engl J Med (1985) 2.36
Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int (2006) 2.33
Processing and proliferative effects of human progastrin in transgenic mice. J Clin Invest (1996) 2.12
Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group. Ann Intern Med (2000) 1.94
A model of lifetime osteoporosis impact. Arch Intern Med (1991) 1.91
An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest (1984) 1.76
Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int (1993) 1.72
Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int (2008) 1.71
Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab (1982) 1.68
Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy (2008) 1.67
Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology (2010) 1.55
Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr (1995) 1.42
Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment. Digestion (1988) 1.34
The absorption of calcium carbonate. Ann Intern Med (1967) 1.29
Dietary intake of selected minerals for the United States population: 1999-2000. Adv Data (2004) 1.27
Calcium and osteoporosis. Nutrition (1998) 1.26
Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res (2010) 1.21
Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med (1987) 1.19
Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology (1990) 1.19
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int (2010) 1.17
Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron (2002) 1.16
The parathyroid glands in experimentally induced hypergastrinemia in the rat. Scand J Gastroenterol (1977) 1.12
Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant (1995) 1.11
Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol (2001) 1.10
Factors influencing the measurement of bioavailability, taking calcium as a model. J Nutr (2001) 1.09
Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs (1998) 1.04
Trophic effects of gastrin. Scand J Gastroenterol Suppl (1991) 0.98
Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine. Scand J Gastroenterol Suppl (1989) 0.93
Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther (1998) 0.93
Chicken parathyroid hormone gene expression in response to gastrin, omeprazole, ergocalciferol, and restricted food intake. Calcif Tissue Int (1997) 0.92
Growth of the parathyroid glands in omeprazole-treated chickens. Scand J Gastroenterol (1994) 0.92
Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo) (1998) 0.92
Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther (1990) 0.91
Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sci (1991) 0.87
Regulation of vitamin D and calcium metabolism after gastrectomy. Gut (1985) 0.87
Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol (1988) 0.86
Radiocalcium absorption is reduced in postmenopausal women with vertebral and most types of peripheral fractures. Osteoporos Int (2003) 0.84
Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women. J Clin Pharmacol (2000) 0.84
Meal effects on calcium absorption. Am J Clin Nutr (1989) 0.84
Effect of L-lactic acid on the absorption of calcium in gastrectomized rats. J Nutr Sci Vitaminol (Tokyo) (1998) 0.82
Low gastric hydrochloric acid secretion and mineral bioavailability. Adv Exp Med Biol (1989) 0.81
Controlled clinical trials of omeprazole in the long-term management of reflux disease. Digestion (1992) 0.79